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Liver and lymph node sinusoidal endothe-
lial cell C-type lectin (LSECtin [CLEC4G])
is a C-type lectin encoded within the
liver/lymph node–specific intercellular ad-
hesion molecule-3–grabbing nonintegrin
(L-SIGN)/dendritic cell–specific intercel-
lular adhesion molecule-3–grabbing non-
integrin (DC-SIGN)/CD23 gene cluster.
LSECtin expression has been previously
described as restricted to sinusoidal en-
dothelial cells of the liver and lymph
node. We now report LSECtin expression
in human peripheral blood and thymic
dendritic cells isolated ex vivo. LSECtin
is also detected in monocyte-derived
macrophages and dendritic cells at the
RNA and protein level. In vitro, interleu-
kin-4 (IL-4) induces the expression of
3 LSECtin alternatively spliced isoforms,
including a potentially soluble form (2
isoform) and a shorter version of the
prototypic molecule (3/4 isoform). LSEC-
tin functions as a pathogen receptor,
because its expression confers Ebola
virus–binding capacity to leukemic cells.
Sugar-binding studies indicate that
LSECtin specifically recognizes N-acetyl-
glucosamine, whereas no LSECtin binding
to Mannan- or N-acetyl-galactosamine–
containing matrices are observed. Anti-
body or ligand-mediated engagement
triggers a rapid internalization of LSECtin,
which is dependent on tyrosine and
diglutamic-containing motifs within the
cytoplasmic tail. Therefore, LSECtin is a
pathogen-associated molecular pattern
receptor in human myeloid cells. In addi-
tion, our results suggest that LSECtin
participates in antigen uptake and inter-
nalization, and might be a suitable tar-
get molecule in vaccination strategies.
(Blood. 2007;109:5337-5345)
© 2007 by The American Society of Hematology
Introduction
The identification of the lectin gene cluster at chromosome
19p13.21 has led to the realization that some C-type lectins are
capable of mediating intercellular adhesion, pathogen-binding, and
antigen internalization for induction of T cell responses.2 The
paradigmatic example of this type of lectin is dendritic cell-specific
intercellular adhesion molecule-3-grabbing nonintegrin (DC-
SIGN), which efficiently internalizes antigens,3 mediates dendritic
cell intercellular adhesions,4 and recognizes a wide range of
microorganisms through binding to mannose- and Lewis-contain-
ing glycans.5 C-type lectins on dendritic cells enhance their ability
for pathogen recognition6 and contribute to modulation of toll-like
receptor (TLR)-initiated signals.7 Consequently, the definition of
the range of dendritic cell lectins and their binding specificities
might provide adequate targets for immune intervention and
prevention of pathogen entrance and spreading.
The lectin gene cluster at chromosome 19p13.2 includes the
genes encoding for the type II C-type lectins DC-SIGN,
liver/lymph node-specific intercellular adhesion molecule-3-
grabbing integrin (L-SIGN), CD23, and liver and lymph node
sinusoidal endothelial cell C-type lectin (LSECtin).1,4,8,9 DC-
SIGN is expressed on myeloid dendritic cells,4,10 and alterna-
tively activated in vitro on macrophages.11 In vivo it is found on
interstitial dendritic cells,12 a subset of CD14 peripheral blood
DC,13 human microvascular endothelial cells,8 and on synovial,
placenta, lymph node, and alveolar macrophages.14-16 By con-
trast, L-SIGN is exclusively expressed on endothelial cells of
the liver, lymph nodes, and placenta,17,18 but not on myeloid
cells.
The LSECtin (CLEC4G) gene is located between the CD23 and
DC-SIGN genes with the three genes arranged in the same
orientation.9 LSECtin encodes a protein with a lectin domain
followed by a 110-residue stalk region, a transmembrane domain,
and a 31-residue cytoplasmic domain.9 LSECtin has been previ-
ously detected on liver and lymph node sinusoidal endothelial cells
at the protein and RNA level.9 LSECtin functions as an attachment
factor for Ebola virus and SARS, but it does not bind HIV or
hepatitis C virus.19 We now describe the expression of LSECtin
isoforms in ex vivo isolated human peripheral blood and thymic
dendritic cells as well as in dendritic cells and macrophages
generated in vitro. LSECtin exhibits ligand-induced internaliza-
tion, and its sugar recognition specificity differs from that of
DC-SIGN. The presence of LSECtin on myeloid cells should
therefore contribute to expanding their antigen-capture and patho-
gen-recognition capabilities.
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Materials and methods
The study described was approved by the Centro de Investigaciones
Biologicas (CSIC) Institutional Review Board. The study did not involve
any direct contact with human subjects.
Cell culture
Human peripheral blood mononuclear cells were isolated from buffy coats
from normal donors over a Lymphoprep (Nycomed Pharma, Oslo, Norway)
gradient according to standard procedures.20 Monocytes were purified from
peripheral blood mononuclear cells by magnetic cell sorting using CD14
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). Monocyte-
derived dendritic cells (MDDC), monocyte-derived macrophages, and
alternatively (AAMØ) or classically (CAMØ) activated macrophages were
generated as previously described.11,20 Isolation of peripheral blood my-
eloid dendritic cells (MyDC)was done with a Blood DC isolation kit
(MACS; Miltenyi Biotec) with some modifications. First, peripheral blood
mononuclear cells were depleted of T cells, NK cells, and monocytic cells
by magnetic separation, and the remaining population was incubated with
monoclonal antibodies (mAbs) to fluorescein isothiocyanate (FITC)-CD4,
phycoerythrin (PE)-labelled CD11c, PE-Cy5-CD14, and PE-Cy5-CD19
and sorted in a FACSVantage cell sorter (BD Biosciences, Franklin Lakes,
NJ). PE-Cy5-positive cells were discarded, and double-positive cells for
CD4 and CD11c were sorted as MyDC (CD11cBDCA2-CD123-). The purity
of the resulting population was confirmed by additional antibody staining.
Human thymic dendritic cells and macrophages were isolated from
thymus fragments removed during corrective cardiac surgery of patients
aged 1 month to 4 years. After Lymphoprep centrifugation, thymocyte cell
suspensions were depleted of T, B, NK cells and CD34 precursors by
magnetic cell sorting (AutoMacs; Miltenyi Biotech) as described.21 Macro-
phages were isolated from the depleted cell fraction by using PE-labeled
anti-CD14mAb and anti-PE microbeads, and exhibited a CD13, CD11c,
CD14 phenotype. Thymic pDC were isolated from the macrophage-
depleted fraction with PE-labeled antiCD123 and antiPE microbeads, and
showed a CD11c-, CD13-, BDCA2, CD123 phenotype. Thymic MyDC
(CD13, CD11cdim, CD14) were isolated from the CD123-negative
fraction with PE-labeled antiCD13 and anti-PE microbeads. Sorted popula-
tions proved to be over 97% pure on reanalysis. Phenotypic analysis was
carried out by indirect immunofluorescence as described.20
The K562 (chronic myelogenous leukemia) and THP-1 (monocytic
leukemia) cell lines were cultured as described20 and THP-1 differentiation
induced with phorbol myristate acetate (PMA) at 10 ng/mL.11 HEK293T
and COS-7 cells were grown in Dulbecco modified eagle medium (DMEM)
with 10% fetal calf serum (FCS) and transfected with Superfect (Qiagen,
Hilden, Germany). Transfection of the pCDNA3.1(-)-based constructs
in K562 cells was accomplished with Superfect or by nucleofection
(Amaxa GmbH, Cologne, Germany). Mutation of residues Y,6 E14E,15
W21GRW24VHW27, and both Y6 and E14E15 were done by site-directed
mutagenesis on LSECtin cDNA cloned in pCDNA3.1(-), which resulted in
the generation of LSECtin Y/F, LSECtin EE/AA, LSECtin 3W/3A, and
LSECtin DM constructs.
Isolation and detection of LSECtin isoform mRNA in distinct
cell types
LSECtin isoforms were isolated by reverse transcriptase-polymerase chain
reaction (RT-PCR) on RNA from MDDC of a healthy donor. Total cellular
RNA was isolated with RNeasy columns (Qiagen). Two micrograms of
RNA was reverse-transcribed and amplification was carried out on 5 L of
each cDNA synthesis reaction in 50 L of solution. After a 5 minute
denaturation step, LSEctin was optimally amplified after 35 cycles of
denaturation (95°C, 45 seconds), annealing (65°C, 30 seconds), and
extension (72°C, 90 seconds), followed by a 10-minute extension step at
72°C. Oligonucleotides used for amplification of the coding region of the
prototypical LSECtin isoform (LSECtin full-length) were LSECtin sense
5-GGGAATTCGCCTGCATCGCCATGGACACC-3) and LSECtin anti-
sense 5-CCCAAGCTTGGGCGGGGTCAGCAGTTGTGC -3). Amplifi-
cation of LSECtin isoforms was accomplished using the primer pairs
LSECtin sense/LSECtin antisense, LSECtin 3/4sense/LSECtin antisense,
and LSECtin 2sense/LSECtin antisense. The oligonucleotide LSECtin
3/4sense 5-CCTATTGTCCAAGGGCTCGGG -3 spans through the exon
2/exon 5 junction. Oligonucleotide LSECtin 2sense 5-CCGAGGAGGTC-
CCCGGAGCCT-3 spans through the exon 1/exon 3 junction. PCR fragments
were resolved in 1.2% agarose gels, purified, cloned, and sequenced. For
eukaryotic expression, the selected LSECtin cDNA isoforms were excised from
TOPO cloning vectors (Invitrogen, Paisley, UK) with EcoRI and HindIII, gel
purified, and ligated into EcoRI- and HindIII-digested pCDNA3.1(-). As a
control in RT-PCR experiments, GAPDH mRNAwas amplified using oligonucle-
otides 5-GGCTGAGAACGGGAAGCTTGTCA-3 and 5-CGGCCAT-
CACGCCACAGT TTC-3, which together amplify a 417 bp fragment.
Images were captured with GelDoc XR (BioRad, Hercules, CA) using
Quantity One-4.5.2 software.
Detection and cell-surface distribution of LSECtin
The cDNA region coding for the extracellular portion of LSECtin (residues
55-293) was generated by polymerase chain reaction with the primers
5-CACCGCCTCCACGGAGCGCGCGG-3 and 5-CCCAAGCTT-
GGGCGGGGTCAGCA GTTGTGC-3. The resulting fragment, which
contains the neck and lectin domains of LSECtin, was cloned in-frame
downstream of the hexahistidine sequence of pET100/D-TOPO (Invitro-
gen) and sequenced. The resulting vector, as well as a positive control
encoding -galactosidase (pET100/D/lacZ), were transformed into BL21
bacteria, and HIS-LSECtin and HIS--gal fusion proteins were purified on
Ni2-nitrilotriacetic acid-agarose (Qiagen). The purified HIS-LSECtin
fusion protein was injected intraperitoneally (three times) into Balb/c mice.
After a final intraperitoneal boost, splenocytes were removed and fused to
SP2 cells at a 1:1 ratio using PEG 1500 (Sigma, Barcelona, Spain), as
described.10 Screening for anti-LSECtin antibodies was done by enzyme-
linked immunosorbent assay using 96-well plates coated with HIS-LSECtin
or HIS--gal (negative control) fusion proteins. Final selection of the
selected hybridoma (SOTO1) was done by immunofluorescence on
HEK293T transiently transfected with an LSECtin-expression vector.
Peptides based on the sequence of the LSECtin neck region (AQAK-
LMEQESALRELREEVTQGLA) and cytoplasmic tail (MDT-
TRYSKWGGSSEEVPGGP WGRWVHWSRR) were synthesized using the
multiple antigen peptide system. New Zealand white rabbits were immu-
nized by subcutaneous injection of each individual peptide or the HIS-
LSECtin protein (0.5 mg of a 1-mg/mL solution in phosphate-buffered
saline) in complete Freud’s adjuvant 1:1 on day 0 and in incomplete Freud’s
adjuvant 1:1 on days 21 and 42. Rabbits were bled on day 49, and serum
was assayed for LSECtin recognition by Western blot. The resulting
antisera (ADS-1 against the neck domain, ADS-3 against the cytoplasmic
tail and ADS-4 against the HIS-LSECtin protein) were subsequently
validated by Western blot on 10 g of cell lysates, as described.20 DC-SIGN
was detected using a polyclonal antiserum against the neck region of the
molecule.22 Isolation of detergent-insoluble and soluble MDDC cell membrane
fractions was done by sucrose gradient ultracentrifugation as described.23
Gene-expression profiling in dendritic cells
RNA from immature and LPS-mature MDDC from two independent
donors, and monocyte-derived macrophages from three independent donors
generated in the presence of either granulocyte macrophage-colony stimu-
lating factor (GM-CSF) or macrophage-colony stimulating factor (M-CSF),
were labeled, processed, and independently hybridized on Codelink human
whole genome DNA chip of the Codelink microarray platform (Amersham
Biosciences, Uppsala, Sweden) containing 55 000 human gene targets.
Scanned images were processed using the Codelink Expression Analysis
Software. Raw data were normalized by the quantile method. Data
corresponding to the experimental groups were analyzed by the Student t
test. The raw P values obtained were adjusted using the control of the false
discovery rate-based procedure and implemented in the multitest package
within the Bioconductor set of routines (www.bioconductor.org).
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Sugar-binding assays
For precipitation of Mannan-, N-acetyl-glucosamine-, and N-acetyl-
galactosamine-binding proteins, K562 cells stably transfected with differ-
ent LSECtin isoforms (3  106) were collected, washed with phosphate-
buffered saline and 1 mM EDTA, and lysed. Then, each lysate was
incubated with 50 L of Mannan-agarose (Sigma), N-acetyl-glucosamine-
agarose (Sigma), or N-acetyl-galactosamine-agarose (Sigma) for 12 hours
at 4°C. After extensive washing, bound proteins were eluted either by
incubation with an excess of the sugars or boiling the agarose beads in 3
Laemmli’s sample buffer. SDS-eluted material was resolved by SDS-PAGE
and LSECtin detection accomplished with specific polyclonal antibodies.
Ebola glycoprotein (GP)1 and virus-binding assays
Ebola virus binding was determined using lentiviral particles pseudotyped
with Ebola virus GP according to a transient transfection protocol previ-
ously described.24 K562 transfectants were challenged with Ebola virus GP
pseudotypes or controls: 25  104 cells were resuspended in 250 L
complete medium and incubated overnight with 250 L of transfection
supernatants. Cells were assayed for luciferase expression 48 hours postinfection.
For inhibition experiments, cells were preincubated for 10 minutes at room
temperature with the preimmune or ADS-1 polyclonal antibodies.
Ebola virus GP1 (envelope glycoprotein of the Zaire strain of Ebola
virus, provided by Dr. Anthony Sanchez, CDC, Atlanta, GA) was fused with
human IgG-Fc by subcloning into pEF-Fc (provided by Dr. J. M.
Casasnovas, CNB, CSIC, Madrid, Spain). The pSyngp120IgG plasmid,
which encodes strain JR-FL HIV gp120 fused to human IgG1Fc, was
obtained from the National Institutes of Health AIDS Research and
Reference Reagent Program (Germantown, MD). For binding experiments,
envelope constructions were transfected into 293T cells and supernatants
collected after 72 hours. MDDC were incubated for 30 minutes at room
temperature with 1:10 dilution of the supernatants in phosphate-buffered
saline, 2% FCS, 4 mM CaCl2. Cells were then washed twice and incubated
with a PE-conjugated goat antihuman IgG-Fc antibody (Immunotech,
Marseille, France). Cells were analyzed in an EPICS-XL cytometer using
the Expo32 software.
LSECtin internalization assays
K562 cells were transiently transfected with LSECtin by Nucleofection
(Amaxa). After 24 hours, cells were washed, resuspended in complete
medium, and incubated with either SOTO1 (for LSECtin), P5D2 (for
CD29), or TS1/18 (for CD18) antibodies for 30 minutes at 4°C to prevent
internalization. After extensive washing, cells were placed at 37°C to allow
internalization to occur, and aliquots were removed after 2, 5, and 15
minutes and immediately placed at 4°C. Then, cells were incubated with a
1:100 dilution of a FITC-labeled goat anti-mouse antibody (Serotec) to
detect cell surface-bound antibodies. All incubations were done in the
presence of 50 g/mL of human IgG to prevent binding through the Fc
portion of the antibodies. In some cases, and to detect internalized
antibodies, cells were fixed and permeabilized (CytoFIX/CytoPerm; BD
Biosciences) before addition of the secondary antibody. Flow cytometry
analysis was performed with an EPICS-CS (Coulter Cientı´fica, Madrid,
Spain) using log amplifiers.
Results
LSECtin mRNA is found in monocyte-derived dendritic cells
and is induced by IL-4
The LSECtin gene lies within the C-type lectin-encoding DC-SIGN/
L-SIGN/CD23 gene cluster on chromosome 19p13.2.1 Although
reported to be exclusively expressed on liver and lymph node
sinusoidal endothelial cells,9 its chromosomal location prompted us
to determine whether LSECtin was found in myeloid cells.
Microarray gene profiling experiments showed that LSECtin mRNA is
expressed in immature and mature human MDDC (Figure 1A).
MDDC contained significantly higher levels of LSECtin RNA than
macrophages generated either in the presence of GM-CSF or
M-CSF (Figure 1B). This set of data was verified by RT-PCR,
because LSECtin mRNA was readily detected in MDDC but was
Figure 1. Expression of LSECtin mRNA in human MDDC. (A) Relative levels of LSECtin, DC-SIGN, and CD23 mRNA in immature and mature MDDC as determined by gene
expression profiling using Codelink Whole Genome Bioarrays. (B) Relative levels of LSECtin mRNA in immature MDDC from two independent donors and monocyte-derived
macrophages generated in the presence of either GM-CSF or M-CSF from three independent donors, as determined by gene expression profiling using Codelink Whole
Genome Bioarrays. Values represent the intensity of expression normalized with the median of all the intensity values in the microarray. (C) Detection of LSECtin mRNA in
hematopoietic cells, cell lines, and in vitro–generated monocyte-derived macrophages and dendritic cells. Total RNA was isolated from the indicated cells and cell lines and
subjected to RT-PCR for amplification of the LSECtin coding region and GAPDH (as control). Analyzed RNA was obtained from endothelial cells from normal and HHT donors,
resting and activated NK cells, the NK3 NK cell clone, peripheral blood T lymphocytes, MDM (interferon--activated, CAMØ; IL-4-activated, AAMØ), immature or mature (with
either lipopolysaccharide or tumor necrosis factor-	) MDDC, and the THP-1 and K562 leukemic cell lines. (D) Schematic representation of the structure of LSECtin mRNA
species amplified by RT-PCR from monocyte-derived dendritic cells. Boxes represent the individual exons, and the arrowhead marks the position of the initiation methionine.
Dark circles indicate the potential N-glycosylation sites.
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absent from peripheral blood lymphocytes, resting or activated NK
cells, or CD34-derived endothelial-like cells (Figure 1C).
LSECtin mRNA was seen in AAM but absent in either naive
or CAM (Figure 1C). Sequencing of the two RT-PCR fragments
routinely generated from MDDC and AAM revealed the exis-
tence of three LSECtin mRNA species, which encode the proto-
typic isoform (full-length, 879 bp), an isoform lacking the transmem-
brane region (2, 768 bp), and an isoform lacking the first two
exons encoding the stalk region (3/4, 762 bp) (Figure 1D). The
full-length isoform was amplified from more than 20 unrelated
MDDC donors, whereas the shorter isoforms were variably de-
tected (data not shown). Therefore, LSECtin mRNA is differen-
tially expressed in monocyte-derived macrophages and dendritic
cells, with the latter containing three distinct mRNA species.
Moreover, LSECtin expression can be detected in macrophages
activated in the presence of IL-4 (AAM).
The presence of LSECtin mRNA in AAM, and the proximity of
the LSECtin gene to that of DC-SIGN, whose expression is IL-4-
dependent,4,10 led us to explore the cytokine responsiveness of the
LSECtin gene. LSECtin mRNA was induced during GM-CSF 
IL-4-promoted MDDC differentiation and was found to be responsive to
the presence of IL-4 (Figure 2A). Besides, and in agreement with the
microarray data, LSECtin mRNA was detected in MDDC matured with
either lipopolysaccharide or tumor necrosis factor-	 (Figure 2A).
Similarly, IL-4 induced the appearance of LSECtin mRNAon proliferat-
ing or PMA-differentiated THP-1 cells, where the three LSECtin
alternatively spliced isoforms were detected (Figure 2B). Because the
combined addition of PMA and IL-4 promotes THP-1 cells to acquire a
dendritic cell-like phenotype,11 these results are compatible with the
presence of LSECtin in MDDC. More importantly, LSECtin mRNA
was detected in ex vivo isolated peripheral blood myeloid dendritic cells
(CD11c BDCA2-CD123-) (Figure 2C) as well as in myeloid and
plasmacytoid thymic dendritic cells and thymic macrophages (Figure
2D). Sequencing of the amplified fragments confirmed the presence of
the full-length and 2 isoforms in both thymic macrophages and
myeloid dendritic cells, which were also seen in human liver RNA as
control (Figure 2D). Altogether, these results indicate that LSECtin
RNA is induced by IL-4 and is expressed by dendritic cells in vivo.
LSECtin protein expression in dendritic cells and macrophages
To confirm these results at the protein level, LSECtin-specific
polyclonal antisera were raised and their specificity tested by
enzyme-linked immunosorbent assay on purified recombinant
HIS-LSECtin. Whereas an anti-HIS serum detected HIS-LSECtin
and HIS--gal to a similar extent, ADS-1 (stalk region-specific)
and ADS-4 antiserum (raised against the extracellular region of the
molecule) exclusively reacted with HIS-LSECtin (Figure 3A). By
contrast, and as expected, ADS-3 antiserum (specific for the
LSECtin cytoplasmic tail) showed no reactivity against the HIS-
LSECtin recombinant protein (Figure 3A). The LSECtin specificity
of the ADS-1 and ADS-4 antisera was further demonstrated by
Western blot after transient transfection of the full-length and the
2 isoforms in COS7 cells (Figure 3B).
The availability of the anti-LSECtin polyclonal antisera allowed
us to address the presence of LSECtin protein in dendritic cells.
Analysis of immature and mature MDDC demonstrated the pres-
ence of an ADS1-reactive protein band that comigrates with the
LSECtin protein generated in COS-7 cells after transient transfec-
tion (Figure 3C). The specificity of the recognition was further
demonstrated by the fact that the detected band was not observed in
the presence of an excess of the immunizing peptide (Figure 3C,
right panel). Moreover, and like DC-SIGN,23 a significant percent-
age of LSECtin molecules were detected in lipid raft-enriched
membrane fractions (Figure 3D), suggesting that LSECtin might
also act as a signaling molecule. Therefore, LSECtin is expressed
in monocyte-derived dendritic cells, where it might contribute to
increase their pathogen-recognition capability.
Detection of LSECtin protein during MDDC differentiation and
macrophage activation confirmed the mRNA data. The IL-4-dependent
in vitro generation of AAMØ resulted in up-regulation of LSECtin,
which was not expressed by CAMØ (Figure 4A). On the other hand,
LSECtin was barely expressed in monocytes, increased after 48 hours in
the presence of GM-CSF and IL-4, and reached maximal levels in
immature MDDC (5-day treatment with GM-CSF IL-4; Figure 4A).
Analysis of MDDC from additional donors confirmed the presence of
LSECtin protein in all cell extracts (data not shown). The presence of
LSECtin was further evaluated by flow cytometry (Figure 4B) and
confocal microscopy (Figure 4C), which revealed the presence of
variable levels of LSECtin protein on the cell surface of monocyte-
derived dendritic cells. Furthermore, flow cytometry revealed high
levels of LSECtin on the cell surface of CD13 CD14 thymic
macrophages, whereas weak levels were found on both thymic myeloid
(CD13 CD14) and plasmacytoid (BDCA2 CD123) dendritic cells
(Figure 4D). Therefore, LSECtin is expressed on the cell surface of in
vitro differentiated (MDDC) and ex vivo isolated (thymic macrophages)
myeloid cells.
Functional characterization of LSECtin
To evaluate the recognition capabilities of LSECtin, stable transfec-
tants were generated in K562 cells (K562-LSECtin), where the
Figure 2. Cytokine-dependence of LSECtin mRNA levels in MDDC and detec-
tion of LSECtin mRNA in ex vivo peripheral blood and thymic dendritic cells. (A)
Monocytes from three independent donors were treated for the indicated periods of
time with either GM-CSF, IL-4, or both cytokines, or allowed to differentiate into
MDDC and further matured with lipopolysaccharide or tumor necrosis factor-	. After
RNA extraction from the distinct cell types, the coding region of the LSECtin mRNA
was amplified and the resulting fragments resolved by agarose gel electrophoresis.
(B) THP-1 leukemic myeloid cells were treated for the indicated periods of time with
IL-4 alone (left panel) or for 96 hours in the presence of IL-4 and the differentiation-
inducing agent PMA (right panel). After RNA extraction from the distinct cell types, the
coding region of the LSECtin mRNA was amplified and the resulting fragments
resolved by agarose gel electrophoresis. (C) RNA was extracted from human myeloid
peripheral blood dendritic cells from three independent donors and LSECtin mRNA
detected by RT-PCR. (D) RNA was extracted from human myeloid and plasmacytoid
thymic dendritic cells, thymic macrophages, or liver biopsies from three independent
donors and LSECtin mRNA detected by RT-PCR. In all cases, GAPDH mRNA was
amplified as a control.
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lectin was readily detectable on the cell surface either by flow
cytometry (Figure 5A) or by immunoprecipitation of biotin-labeled
cell surface proteins (Figure 5B) with polyclonal antisera (ADS-3,
ADS-4) or the anti-LSECtin SOTO1 monoclonal antibody. Whereas
K562-LSECtin and mock-transfected cells exhibited similar bind-
ing of VSV, expression of full-length LSECtin conferred K562
cells the ability to bind viral particles pseudotyped with Ebola or
Marburg virus GP (Figure 5C). The viral binding to full-length
LSECtin was almost completely abrogated in the presence of the
ADS-1 polyclonal antiserum (Figure 5D), confirming the specific-
ity of the interaction. In agreement with these results, K562-
LSECtin cells specifically bound soluble Ebola virus glycoprotein
GP1 (see subsequently). LSECtin also displayed Ebola GP1-
binding ability when expressed on in vitro generated dendritic
cells. Although HIV gp120 binding to MDDC was exclusively
inhibited by anti-DC-SIGN antibodies, Ebola GP1 binding to
MDDC was partially dependent on LSECtin (Figure 5E). In fact,
complete abrogation of GP1 binding to MDDC was only observed
in the presence of anti-LSECtin antiserum (ADS-1) and anti-DC-SIGN
antibodies (MR1) (Figure 5E). Therefore, LSECtin displays pathogen-
recognition capability when expressed on hematopoietic cells.
To compare the sugar-specificity of LSECtin with that of
DC-SIGN, which acts as an Ebola virus attachment factor,25 we
performed sugar affinity experiments by incubation of extracts
from DC-SIGN- and LSECtin-transfected K562 cells with Man-
nan-, N-acetyl-glucosamine-, and N-acetyl-galactosamine-agarose.
Both the full-length and the 3/4 isoform were not retained by
Mannan-agarose, whereas DC-SIGN bound to this matrix (Figure
6A). However, both LSECtin isoforms were specifically retained
by N-acetyl-glucosamine-agarose (Figure 6B) but not by N-acetyl-
galactosamine-agarose (Figure 6C). LSECtin from MDDC exhib-
ited the same sugar specificity, because it was retained by
N-acetyl-glucosamine-agarose but not by Mannan-agarose (Figure
6D). Therefore, and in agreement with the results of pathogen-
binding experiments, LSECtin exhibits a sugar-binding specificity
that differs from that of the structurally related DC-SIGN lectin on
both K562 transfectants and in vitro generated dendritic cells.
Finally, we evaluated the ability of LSECtin to act as an
antigen-capturing receptor by performing internalization experi-
ments with LSECtin-specific ligands. Engagement of LSECtin by
SOTO1 led to a rapid loss of the molecule from the cell surface
(50% reduction after 2 minutes, 80% after 15 minutes) but did not
affect the cell surface levels of CD29 (Figure 7A). To find out
whether antibody engagement triggered LSECtin internalization or
shedding, a similar experiment was performed using permeabilized
cells. No reduction in LSECtin levels was observed when cells
were permeabilized before the addition of the secondary fluores-
cent antibody (Figure 7A), although to a lower extent, the addition
of GP1 onto K562-LSECtin cells also resulted in down-regulation
of LSECtin without affecting the expression of the CD29 integrin
subunit (Figure 7B). Altogether, these results indicate that LSECtin
is internalized on ligation on the cell surface and might thus
participate in antigen binding and uptake at the early stages of an
immune response.
Figure 3. Expression of LSECtin in human MDDC. (A) Specificity of polyclonal antisera against LSECtin by enzyme-linked immunosorbent assay. High protein-binding
96-well plates were coated with either purified HIS-LSECtin, purified gal-HIS, or BSA. After washing, wells were treated with either a monoclonal antibody against the HIS
epitope (anti-His), a control monoclonal antibody (antiCD86), polyclonal antisera against LSECtin (ADS-1, ADS-3, ADS-4), or the corresponding preimmune sera. Bound
antibodies were detected using HRP-conjugated goat antirabbit and goat antimouse polyclonal antisera. Quantification was done on a microplate enzyme-linked
immunosorbent assay reader at 450 nm. (B) Specificity of polyclonal antisera against LSECtin by Western blot. Whole cell extracts were obtained from COS-7 cells transiently
transfected with full-length LSECtin, the 2 LSECtin isoform (LSECtin 2), or mock-transfected cells (Mock). Ten micrograms of each whole cell extract was subjected to
Western blot using the ADS-1 or ADS-4 polyclonal antisera specific for LSECtin. (C) Whole cell lysates were obtained from immature and mature MDDC, and 10 g of each
extract was subjected to Western blot using the ADS-1 anti-LSECtin polyclonal antiserum either alone (left panel) or in the presence of an excess of the immunizing peptide
(right panel). Lysates from mock- and LSECtin-transfected COS-7 cells were included as controls. The position of the LSECtin protein is indicated by an arrowhead, and
nonspecific bands are denoted as NS. (D) Immature MDDC were lysed in 1% Brij 98 lysis buffer at 37°C and fractionated by sucrose density gradient centrifugation. The
low-density Brij 98-insoluble fractions 2-4 (lanes 2-4, Rafts) and the high-density Brij 98-soluble fractions 6-8 (lanes 6-8, soluble) were separated by 12.5% SDS-PAGE under
reducing conditions, and the distribution of LSECtin was determined by immunoblotting. Cytoskeletal-associated Rafts (CAR), obtained by solubilization of the cell pellet with
Brij98  Octyl D-glucoside in lysis buffer, were analyzed in parallel (lane 9, CAR). Ten micrograms of each fraction was subjected to Western blot, and the distribution of
LSECtin and ganglioside GM1 in the distinct fractions was determined by immunoblotting with the ADS-1 polyclonal antisera (LSECtin) or cholera toxin-HRP (GM1). The
experiment was done on MDDC from two independent donors, and one of them is shown.
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Ligand-induced endocytosis is a property shared by lectins
involved in antigen capture and presentation and is dependent
on the presence of internalization motifs in the cytoplasmic tail.2
To determine the molecular basis for the antibody-induced
LSECtin internalization, two potential internalization motifs
similar to those present in other lectins (Y6SKW and E14E15)
were mutated and assayed for internalization capability. Muta-
tion of either Y6 (to F6) or E14E15 (to A14A15) significantly
reduced the ligand-induced internalization of LSECtin (Figure
7C). Although mutation of Y6 exhibited a stronger effect at early
time points (2 minutes), disruption of both motifs (LSECtin
DM) reduced internalization to a higher extent than each
individual mutations (after 5 or 15 minutes) (Figure 7C). By
contrast, mutation of the three tryptophan residues within the
cytoplasmic tail (W21GRW24VHW,27 LSECtin 3W/3A) had no
effect (Figure 7C). Therefore, the ability of LSECtin to be
internalized on ligand binding is dependent on the integrity of
both Y6SKW and E14E15 motifs in the cytoplasmic tail. LSECtin
was found to be internalized at a similar rate in MDDC, because
only 20% of LSECtin molecules remain on the cell membrane
15 minutes after antibody engagement (Figure 7D). Therefore,
LSECtin is internalized after engagement in both transfectants
and monocyte-derived dendritic cells, suggesting its involvement
in antigen capture and internalization by myeloid cells.
Discussion
The gene cluster in chromosome 19p13.2 includes the C-type
lectin-encoding genes CD23, DC-SIGN (CD209), LSECtin, and
DC-SIGNR, with the first three of them arranged adjacent to one
another and in the same orientation. In the present report, we
demonstrate that LSECtin, originally defined as a liver and lymph
node sinusoidal-specific lectin,9 can be induced by IL-4 on human
peripheral blood monocytes and is expressed by in vitro generated
dendritic cells and alternatively activated macrophages as well as
by ex vivo thymic myeloid cells. The IL-4 dependence of LSECtin
expression resembles the cytokine responsiveness of the DC-SIGN
and CD23 genes, whose expression is either induced or up-
regulated by IL-4,10,26 and suggests a common mechanism for their
coordinated up-regulation in IL-4-treated monocytes. Moreover,
and like DC-SIGN and CD23, LSECtin is internalized on ligand
binding. Therefore, DC-SIGN, CD23, and LSECtin comprise a
cluster of structurally related lectin genes expressed on myeloid
cells regulated by IL-4 and involved in antigen capture. At present,
we have no explanation for the discrepancy between the previously
reported lack of LSECtin mRNA detection in MDDC9 and the data
presented in this article, especially considering that MDDC were
generated following an identical protocol. LSECtin expression in
MDDC is consistent with its induction in alternatively activated
macrophages, which share a number of membrane markers with
MDDC,11 and with the presence of LSECtin mRNA in peripheral
blood and thymic dendritic cells. Therefore, it can be concluded
that LSECtin exhibits a wider cell type distribution than DC-SIGN
and CD23 being expressed in both hematopoietic and nonhematopi-
etic cell lineages.
Like in the case of other C-type lectins,27 three distinct
alternatively spliced isoforms can be predicted for LSECtin based
on the sequences of the amplified mRNAs. The LSECtin gene gives
Figure 4. LSECtin expression on the cell surface of monocyte-derived dendritic cells and thymic-cell subsets. (A) Cell extracts were obtained from monocytes along
the MDDC differentiation pathway by treating them with GM-CSF plus IL-4 for the indicated periods of time. In parallel, extracts were obtained from GM-CSF-generated
macrophages after a 48-hour treatment with medium (MDM), IL-4 (AAMØ), or interferon- (CAMØ). In all cases, 10 g of each lysate was subjected to Western blot for
detection of LSECtin with the ADS-1 polyclonal antiserum and -actin expression determined in parallel for loading control purpose. (B) Cell surface expression levels of
LSECtin in monocyte-derived dendritic cells from three independent donors as determined with the antiLSECtin SOTO1 monoclonal antibody. The supernatant from the
P3  63 myeloma was used as negative control (X63). (C) MDDC were allowed to differentiate on glass coverslips, fixed (paraformaldehyde 2%), washed, and incubated with
either a polyclonal antiserum against LSECtin (ADS-1) or preimmune serum. After washing, cells were incubated with a 1:500 dilution of Alexa 488-labeled goat anti-rabbit IgG
(F(ab)2) antiserum. Nuclei were counterstained with 4,6-diamidino-2-fenilindol diclorhidrato (DAPI). Coverslips were mounted in Dako Cytomation fluorescent mounting
medium (Dako, Glostrup, Denmark) and representative fields photographed through an HCX PL APO lens (63.0  1.40 oil objective), with a 1.400000 numerical aperture on
a TCS-SP2-ADBS confocal laser LEICA scanning system (LEICA MICROSYSTEMS GmbH, Wetzlar, Germany). (D) Expression of LSECtin in human thymic cell populations.
Human thymic cell preparations were depleted of thymocytes by centrifugation on Ficoll after rosetting with sheep erythrocytes. The resulting population was then stained with
either PE-labeled anti-CD123 and FITC-labeled BDCA2 or with FITC-labeled anti-CD14 and PE-labeled anti-CD13 antibodies. The BDCA2 CD123 (plasmacytoid DC
[pDC]), CD14 CD13 (macrophages [MØ]), and CD14CD13 (myeloid DC [MyDC]) subsets (left panels) were simultaneously stained with the anti-LSECtin SOTO1
monoclonal antibody followed by incubation with an APC-labeled goat anti-mouse antiserum (right panels).
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rise to both membrane-bound and a transmembrane-lacking poten-
tially soluble isoform (2 isoform). The relative levels of the
distinct LSECtin mRNA species appear to be dependent on the cell
type: thymic macrophages exhibit equivalent amounts of LSECtin
mRNA coding for full-length and truncated (2 and 3/4) mol-
ecules, whereas thymic dendritic cells almost exclusively contain
LSECtin mRNA for the shorter versions of the molecule. Interest-
ingly, and as in the case of DC-SIGN,27 a significant percentage of
LSECtin mRNA species coding for a transmembrane domain-
lacking potentially soluble isoform (LSECtin 2) have been
detected not only in dendritic cells (generated in vitro and isolated
ex vivo), but also in alternatively activated macrophages and even
in the THP-1 cell line. In fact, and unlike full-length LSECtin, the
LSECtin 2 isoform can be detected in the supernatant of
transfected cells (data not shown), suggesting that it is stable in the
extracellular milieu and that it might function as an opsonizing
agent. In this regard, a large number of cell surface lectins and
lectin-like molecules exhibit potentially soluble isoforms,28 and
several soluble lectins display pathogen-recognition capability.29
The soluble form of CD23 is found in serum and is generated by
endogenous or exogenous proteases that cleave CD23 from the
cell surface26 and has been described as regulating IgE synthe-
sis.30 The availability of the reagents described in the present
article will allow us to determine whether LSECtin can be
Figure 5. Pathogen-recognition ability of LSECtin. (A) Generation of LSECtin stable transfectants. K562 cells were transfected with an empty vector (Mock) or with an LSECtin
expression vector (LSECtin) and grown in G418-containing selective medium. LSECtin expression was determined by indirect immunofluorescence with a polyclonal antiserum against
LSECtin (ADS-4) or the SOTO1 anti-LSECtin monoclonal antibody. Preimmune polyclonal antiserum (Preimm.) and the supernatant from the P3 63 myeloma (X63) were used as
controls. (B) Mock-transfected K562 cells (Mock) or K562-LSECtin cells stably transfected with full-length LSECtin (LSECtin) were surface-labeled with a water-soluble and
membrane-impermeable biotin derivative (EZ-linked Sulfo-NHS-LC-Biotin; Pierce, Rockford, IL), washed, lysed, and immunoprecipitated with polyclonal antisera against LSECtin (left
panel,ADS-3; right panel,ADS-4) or preimmune serum. Precipitated material was resolved by SDS-PAGE under reducing conditions and subjected to Western blot with HRP-streptavidin.
(C) Binding of Ebola and Marburg pseudovirus to LSECtin-transfected cells. Mock-transfected and K562-LSECtin transfectants were challenged with vesicular stomatitis virus (VSV),
Marburg or Ebola virus GP pseudotypes, and cells were assayed for luciferase expression 48 hours postinfection. (D) Inhibitory effect of the ADS-1 anti-LSECtin polyclonal antiserum on
the Ebola pseudovirus binding to LSECtin. The experiment was performed like in D, but cells were preincubated for 10 minutes at room temperature with the preinmune or ADS-1
polyclonal antibodies before viral addition. (E) Binding of Ebola virus GP1 and HIV gp120 to MDDC. Cells were incubated with the recombinant proteins either in the absence or in the
presence of antibodies against DC-SIGN (MR1), LSECtin (ADS-1), or both and binding measured by flow cytometry. Protein binding is measured as relative fluorescence, which indicates
the binding observed in each experimental condition relative to the binding detected in the presence of preimmune antiserum (considered as 100). The level of expression of LSECtin and
DC-SIGN in the assayed MDDC is illustrated in the upper panel.
Figure 6. Binding specificity of LSECtin in dendritic cells and
transfectants. Whole cell lysates from K562 cells stably transfected
with full-length LSECtin(LSECtin), the 3/4 isoform (LSECtin 3/4),
DC-SIGN, or mock-transfected (Mock) were loaded onto Mannan- (A),
N-acetyl-glucosamine- (NAcGlc, B), or N-acetyl-galactosamine (NAc-
Gal)-agarose (C) and retained proteins eluted with SDS sample buffer
(SDS-eluted) and analyzed by Western blot using the ADS-1 anti-
LSECtin polyclonal antiserum. As a control, aliquots from nonretained
material (supernatant) were analyzed in parallel. (D) Whole cell
lysates from monocyte-derived dendritic cells were loaded onto
Mannan- or N-acetyl-glucosamine- (NAcGlc)-agarose and retained
proteins eluted with SDS sample buffer (SDS-eluted) and analyzed by
Western blot using polyclonal antisera against LSECtin (ADS-1) or
DC-SIGN (DSG1).
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detected in serum and whether soluble LSECtin might also
influence the IgE network.
Evaluation of the sugar specificity in precipitation assays has
revealed that LSECtin interacts with N-acetyl-glucosamine
(NAcGlc) but is not retained by N-acetyl-galactosamine (NAcGal)
or Mannan. Although previously described to interact with Man-
nan,9 our results are in agreement with the lack of Mannan-binding
reported by Gramberg et al,19 despite the presence of the EPN motif
in calcium-binding site 2 that mediates Mannose/NAcGlc binding
in other C-type lectins.31 Thus, LSECtin specificity is distinct from
CD23, which binds better to Gal-NAcGal-containing structures
than to Gal-NAcGlc-structures,26 and would also differ from
DC-SIGN in their ability to be retained by Mannose-containing
matrices (Figure 6). Therefore, available data suggest that the three
lectins encoded within the 19p13.2 gene cluster are not functionally
redundant in terms of sugar-binding specificity. The different
carbohydrate specificity of DC-SIGN and LSECtin is further
suggested by the distinct aggregation behavior of their correspond-
ing transfectants in K562 cells.32
The nonredundant sugar specificity of the three lectins would
also imply that DC-SIGN, CD23, and LSECtin differ in their
pathogen-recognition capabilities. In fact, our results and those of
others19 indicate that this is indeed the case, because LSECtin does
not mediate the binding and uptake of DC-SIGN-interacting
pathogens such as HIV, hepatitis C virus,19 Leishmania, Candida,
or Aspergillus (data not shown). However, although the failure
of K562-LSECtin to capture these pathogens is in agreement
with the inability of Mannan-agarose matrix to retain LSECtin,
these results should be interpreted with caution, because DC-
SIGN-dependent pathogen-recognition activities are greatly
dependent on the cell surface level of expression.22 Therefore,
an extensive analysis of the sugar-binding specificity of LSECtin
should be performed before ruling out its ability to interact with
DC-SIGN-interacting pathogens.
Several distinct motifs (tyrosine-based, dileucine-based, glu-
tamic-rich sequences) have been identified as responsible for the
internalization of dendritic cell lectins involved in antigen capture
for subsequent presentation.33 In the case of LSECtin, its ligand-
induced internalization ability is dependent on two internalization
motifs (Y6SKW and E14E15) within the cytoplasmic tail of the
molecule, which is devoid of a dileucine motif. Analysis of the
LSECtin cytoplasmic tail reveals the presence of a tryptophan-rich
sequence that conforms to the consensus WXYWXYWXY, where
X is a small amino acid and Y is a positively charged residue.
Although this sequence resembles motifs found in cytoskeletal and
extracellular proteins, its disruption had no effect on LSECtin
internalization, which leads us to hypothesize its involvement in
signal transduction. The internalization ability of LSECtin fits well
with the effector functions of macrophages and dendritic and
sinusoidal cells, which constitutively capture extracellular material
either for scavenging purposes or for antigen processing and
presentation. Along this line, the presence of LSECtin in thymic
macrophages and dendritic cells, which are involved in central
tolerance induction,34 is suggestive of a role for LSECtin in antigen
presentation and tolerance. On the other hand, the expression of
LSECtin in MDDC indicates that the molecule could be a potential
Figure 7. Ligand-induced internalization of LSECtin in transfectants and monocyte-derived dendritic cells. (A) Monoclonal antibody-induced internalization of LSECtin
in K562 transfectants. K562-LSECtin cells were incubated with either the SOTO1 (antiLSECtin) or the P5D2 (antiCD29) antibodies for 30 minutes at 4°C. After extensive
washing in cold phosphate-buffered saline, cells were transferred to 37°C for the indicated time points, fixed, and the presence of cell surface-bound antibodies detected with
FITC-labeled F(ab)2 anti-mouse IgG. Where indicated, cells were fixed and permeabilized before addition of the fluorescent secondary antibody (Perm). Values represent the
fluorescence intensity of the cells at the distinct time points relative to the fluorescence intensity of control cells maintained at 4°C. One representative experiment of two is
shown. (B) Ebola GP1-induced internalization of LSECtin. K562-LSECtin cells were either untreated or incubated with Ebola virus GP1-Fc (GP1) for 10 minutes at 37°C,
transferred to 4°C, and the expression of LSECtin or the CD29 integrin (negative control) determined by indirect immunofluorescence with SOTO1 or P5D2 monoclonal
antibodies and FITC-labeled F(ab)2 anti-mouse IgG. Values represent the fluorescence intensity of the cells at the distinct time points relative to the fluorescence intensity of
control cells maintained at 4°C. Mean 
 standard deviation of three independent experiments is shown (*P  0.001). (C) Cytoplasmic motifs involved in LSECtin
ligand-induced internalization. K562 cells were transiently transfected with expression vectors for WT LSECtin or LSECtin mutated at Y6 (LSECtin Y/F), E14E15 (LSECtin
EE/AA), W21GRW24VHW27 (LSECtin 3W/3A), or at both Y6 and E14E15 (LSECtin DM). Twenty-four hours later, cells were washed and incubated with the SOTO1 (anti-LSECtin)
or the P5D2 (anti-CD29) antibodies for 30 minutes at 4°C. After extensive washing in cold phosphate-buffered saline, cells were transferred to 37°C for the indicated time points
(2, 5, 15 minutes), placed on ice, and the presence of cell surface-bound antibodies detected with FITC-labeled F(ab)2 anti-mouse IgG. Values represent the fluorescence
intensity of the cells at the distinct time points relative to the fluorescence intensity of control cells maintained at 4°C. Shown are the mean and standard deviation of three
independent experiments. (D) Monoclonal antibody-induced internalization of LSECtin in MDDC. MDDC were incubated with either the SOTO1 (anti-LSECtin) or the TS1/18
(anti-CD18) antibodies for 30 minutes at 4°C. After extensive washing in cold phosphate-buffered saline, cells were transferred to 37°C for the indicated time points and
immediately transferred to 4°C. The presence of cell surface-bound antibodies was detected with FITC-labeled F(ab)2 anti-mouse IgG. Relative expression of each protein
was measured by multiplying the percentage of marker-positive cells by their mean fluorescence intensity and is referred to the value obtained for control cells maintained at
4°C (considered as 100). One representative experiment of two is shown.
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target molecule in vaccination strategies, a capacity already
demonstrated for DEC-205 and DC-SIGN.35,36 If so, determination
of the LSECtin specificity might be helpful to understand whether
the molecule participates in triggering immune responses (through
recognition of PAMPs) or preferentially acts as a tolerance-
inducing receptor (through capture of self-antigens).
Acknowledgments
This work was supported by the Ministerio de Educacio´n y Ciencia
(grants SAF2005-0021, AGL2004-02148-ALI, and GEN2003-
20649-C06-01/NAC) and Fundacio´n para la Investigacio´n y Preven-
cio´n del SIDA en Espan˜a (FIPSE 36422/03) to ALC. A.D.S. was
supported by a FPI predoctoral grant (BES2004-4405) from
Ministerio de Educacio´n y Ciencia (Spain).
Authorship
Contribution: A.D.S. designed the research and performed the
experiments; L.A.F., E.G.M., L.M.P., and P.M. performed the
research (lipid raft preparation, thymic cell separation, Ebola-
binding assays); M.L.T., M.C., M.Z., R.D., and F.B. provided
reagents and supervised individual experiments; and A.L.C. super-
vised research and wrote the paper.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Angel L. Corbı´, Centro de Investigaciones
Biolo´gicas, Consejo Superior de Investigaciones Cientı´ficas,
Vela´zquez 144, 28 006 Madrid, Spain; e-mail: acorbi@cib.csic.es.
References
1. Soilleux EJ, Barten R, Trowsdale J. DC-SIGN; a
related gene, DC-SIGNR; and CD23 form a clus-
ter on 19p13. J Immunol. 2000;165:2937-2942.
2. Cambi A, Figdor CG. Dual function of C-type lec-
tin-like receptors in the immune system. Curr
Opin Cell Biol. 2003;15:539-546.
3. Schjetne KW, Thompson KM, Aarvak T, Flecken-
stein B, Sollid LM, Bogen B. A mouse C kappa-
specific T cell clone indicates that DC-SIGN is an
efficient target for antibody-mediated delivery of T
cell epitopes for MHC class II presentation. Int
Immunol. 2002;14:1423-1430.
4. Geijtenbeek TB, Torensma R, van Vliet SJ, et al.
Identification of DC-SIGN, a novel dendritic cell-
specific ICAM-3 receptor that supports primary
immune responses. Cell. 2000;100:575-585.
5. Feinberg H, Mitchell DA, Drickamer K, Weis WI.
Structural basis for selective recognition of oligo-
saccharides by DC-SIGN and DC-SIGNR. Sci-
ence. 2001;294:2163-2166.
6. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin
receptors on dendritic cells and Langerhans cells.
Nat Rev Immunol. 2002;2:77-84.
7. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape
mechanism for pathogens. Nat Rev Immunol.
2003;3:697-709.
8. Bashirova AA, Geijtenbeek TB, van Duijnhoven
GC, et al. A dendritic cell-specific intercellular ad-
hesion molecule 3-grabbing nonintegrin (DC-
SIGN)-related protein is highly expressed on hu-
man liver sinusoidal endothelial cells and
promotes HIV-1 infection. J Exp Med. 2001;193:
671-678.
9. Liu W, Tang L, Zhang G, et al. Characterization of
a novel C-type lectin-like gene, LSECtin: demon-
stration of carbohydrate binding and expression
in sinusoidal endothelial cells of liver and lymph
node. J Biol Chem. 2004;279:18748-18758.
10. Relloso M, Puig-Kroger A, Pello OM, et al. DC-
SIGN (CD209) expression is IL-4 dependent and
is negatively regulated by IFN, TGF-beta, and
anti-inflammatory agents. J Immunol. 2002;168:
2634-2643.
11. Puig-Kroger A, Serrano-Gomez D, Caparros E, et
al. Regulated expression of the pathogen recep-
tor dendritic cell-specific intercellular adhesion
molecule 3 (ICAM-3)-grabbing nonintegrin in
THP-1 human leukemic cells, monocytes, and
macrophages. J Biol Chem. 2004;279:25680-
25688.
12. Soilleux EJ, Morris LS, Leslie G, et al. Constitu-
tive and induced expression of DC-SIGN on den-
dritic cell and macrophage subpopulations in situ
and in vitro. J Leukoc Biol. 2002;71:445-457.
13. Engering A, Van Vliet SJ, Geijtenbeek TB, Van
Kooyk Y. Subset of DC-SIGN() dendritic cells in
human blood transmits HIV-1 to T lymphocytes.
Blood. 2002;100:1780-1786.
14. van Lent PL, Figdor CG, Barrera P, et al. Expres-
sion of the dendritic cell-associated C-type lectin
DC-SIGN by inflammatory matrix metalloprotein-
ase-producing macrophages in rheumatoid arthri-
tis synovium and interaction with intercellular ad-
hesion molecule 3-positive T cells. Arthritis
Rheum. 2003;48:360-369.
15. Engering A, van Vliet SJ, Hebeda K, et al. Dy-
namic populations of dendritic cell-specific
ICAM-3 grabbing nonintegrin-positive immature
dendritic cells and liver/lymph node-specific
ICAM-3 grabbing nonintegrin-positive endothelial
cells in the outer zones of the paracortex of hu-
man lymph nodes. Am J Pathol. 2004;164:1587-
1595.
16. Granelli-Piperno A, Pritsker A, Pack M, et al. Den-
dritic cell-specific intercellular adhesion molecule
3-grabbing nonintegrin/CD209 is abundant on
macrophages in the normal human lymph node
and is not required for dendritic cell stimulation of
the mixed leukocyte reaction. J Immunol. 2005;
175:4265-4273.
17. Mukhtar M, Harley S, Chen P, et al. Primary iso-
lated human brain microvascular endothelial cells
express diverse HIV/SIV-associated chemokine
coreceptors and DC-SIGN and L-SIGN. Virology.
2002;297:78-88.
18. Pohlmann S, Soilleux EJ, Baribaud F, et al. DC-
SIGNR, a DC-SIGN homologue expressed in en-
dothelial cells, binds to human and simian immu-
nodeficiency viruses and activates infection in
trans. Proc Natl Acad Sci USA. 2001;98:2670-
2675.
19. Gramberg T, Hofmann H, Moller P, et al. LSECtin
interacts with filovirus glycoproteins and the spike
protein of SARS coronavirus. Virology. 2005;340:
224-236.
20. Dominguez-Soto A, Puig-Kroger A, Vega MA,
Corbi AL. PU.1 regulates the tissue-specific ex-
pression of dendritic cell-specific intercellular ad-
hesion molecule (ICAM)-3-grabbing nonintegrin.
J Biol Chem. 2005;280:33123-33131.
21. de Yebenes VG, Carrasco YR, Ramiro AR, Tor-
ibio ML. Identification of a myeloid intrathymic
pathway of dendritic cell development marked by
expression of the granulocyte macrophage-
colony-stimulating factor receptor. Blood. 2002;
99:2948-2956.
22. Serrano-Gomez D, Dominguez-Soto A, Ancochea
J, Jimenez-Heffernan JA, Leal JA, Corbi AL. Den-
dritic cell-specific intercellular adhesion molecule
3-grabbing nonintegrin mediates binding and in-
ternalization of Aspergillus fumigatus conidia by
dendritic cells and macrophages. J Immunol.
2004;173:5635-5643.
23. Caparros E, Munoz P, Sierra-Filardi E, et al. DC-
SIGN ligation on dendritic cells results in ERK
and PI3K activation and modulates cytokine pro-
duction. Blood. 2006;107:3950-3958.
24. Wool-Lewis RJ, Bates P. Characterization of
Ebola virus entry by using pseudotyped viruses:
identification of receptor-deficient cell lines. J Vi-
rol. 1998;72:3155-3160.
25. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi
AL, Delgado R. C-type lectins DC-SIGN and L-
SIGN mediate cellular entry by Ebola virus in cis
and in trans. J Virol. 2002;76:6841-6844.
26. Kijimoto-Ochiai S. CD23 (the low-affinity IgE re-
ceptor) as a C-type lectin: a multidomain and mul-
tifunctional molecule. Cell Mol Life Sci. 2002;59:
648-664.
27. Mummidi S, Catano G, Lam L, et al. Extensive
repertoire of membrane-bound and soluble den-
dritic cell-specific ICAM-3-grabbing nonintegrin 1
(DC-SIGN1) and DC-SIGN2 isoforms. Inter-indi-
vidual variation in expression of DC-SIGN tran-
scripts. J Biol Chem. 2001;276:33196-33212.
28. Cambi A, Koopman M, Figdor CG. How C-type
lectins detect pathogens. Cell Microbiol. 2005;7:
481-488.
29. Ji X, Gewurz H, Spear GT. Mannose binding lec-
tin (MBL) and HIV. Mol Immunol. 2005;42:145-
152.
30. Shakib F, Schulz O, Sewell H. A mite subversive:
cleavage of CD23 and CD25 by Der p 1 en-
hances allergenicity. Immunol Today. 1998;19:
313-316.
31. Drickamer K. Engineering galactose-binding ac-
tivity into a C-type mannose-binding protein. Na-
ture. 1992;360:183-186.
32. de la Rosa G, Yanez-Mo M, Samaneigo R, et al.
Regulated recruitment of DC-SIGN to cell-cell
contact regions during zymosan-induced human
dendritic cell aggregation. J Leukoc Biol. 2005;
77:699-709.
33. Mahnke K, Knop J, Enk AH. Induction of tolero-
genic DCs: ’you are what you eat.’ Trends Immu-
nol. 2003;24:646-651.
34. Wu L, Shortman K. Heterogeneity of thymic den-
dritic cells. Semin Immunol. 2005;17:304-312.
35. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nus-
senzweig MC, Steinman RM. Efficient targeting of
protein antigen to the dendritic cell receptor DEC-
205 in the steady state leads to antigen presenta-
tion on major histocompatibility complex class I
products and peripheral CD8 T cell tolerance. J
Exp Med. 2002;196:1627-1638.
36. Tacken PJ, de Vries IJ, Gijzen K, et al. Effective
induction of naive and recall T-cell responses by
targeting antigen to human dendritic cells via a
humanized anti-DC-SIGN antibody. Blood. 2005;
106:1278-1285.
LSECtin EXPRESSION IN MYELOID CELLS 5345BLOOD, 15 JUNE 2007  VOLUME 109, NUMBER 12
For personal use only.on June 4, 2016. by guest  www.bloodjournal.orgFrom 
online March 5, 2007
 originally publisheddoi:10.1182/blood-2006-09-048058
2007 109: 5337-5345
 
 
Maria L. Toribio, Rafael Delgado and Angel L. Corbi
Maria Colmenares, Marisa Naranjo-Gomez, Francesc E. Borras, Pilar Munoz, Mercedes Zubiaur, 
Angeles Dominguez-Soto, Laura Aragoneses-Fenoll, Enrique Martin-Gayo, Lorena Martinez-Prats,
 
pathogen binding by human myeloid cells
related lectin LSECtin mediates antigen capture and−The DC-SIGN
 
http://www.bloodjournal.org/content/109/12/5337.full.html
Updated information and services can be found at:
 (5390 articles)Immunobiology    
 (790 articles)Cell Adhesion and Motility    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on June 4, 2016. by guest  www.bloodjournal.orgFrom 
